Variations in the neuropathology of familial Alzheimer's disease

被引:100
|
作者
Shepherd, Claire [1 ,2 ]
McCann, Heather [1 ,2 ]
Halliday, Glenda Margaret [1 ,2 ]
机构
[1] Prince Wales Med Res Inst, Randwick, NSW 2031, Australia
[2] Univ New S Wales, Sydney, NSW, Australia
关键词
Alzheimer's disease; Presenilin; Amyloid precursor protein; Neuropathology; Familial; AMYLOID PRECURSOR PROTEIN; COTTON WOOL PLAQUES; HEREDITARY CEREBRAL-HEMORRHAGE; PAIRED HELICAL FILAMENTS; GAMMA-SECRETASE ACTIVITY; GLYCOGEN-SYNTHASE KINASE-3-BETA; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; APP LOCUS DUPLICATION; A-BETA;
D O I
10.1007/s00401-009-0521-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes cause autosomal dominant familial Alzheimer's disease (AD). PSEN1 and PSEN2 are essential components of the gamma-secretase complex, which cleaves APP to affect A beta processing. Disruptions in A beta processing have been hypothesised to be the major cause of AD (the amyloid cascade hypothesis). These genetic cases exhibit all the classic hallmark pathologies of AD including neuritic plaques, neurofibrillary tangles (NFT), tissue atrophy, neuronal loss and inflammation, often in significantly enhanced quantities. In particular, these cases have average greater hippocampal atrophy and NFT, more significant cortical A beta 42 plaque deposition and more substantial inflammation. Enhanced cerebral A beta 40 angiopathy is a feature of many cases, but particularly those with APP mutations where it can be the dominant pathology. Additional frontotemporal neuronal loss in association with increased tau pathology appears unique to PSEN mutations, with mutations in exons 8 and 9 having enlarged cotton wool plaques throughout their cortex. The mechanisms driving these pathological differences in AD are discussed.
引用
收藏
页码:37 / 52
页数:16
相关论文
共 50 条
  • [1] Variations in the neuropathology of familial Alzheimer’s disease
    Claire Shepherd
    Heather McCann
    Glenda Margaret Halliday
    [J]. Acta Neuropathologica, 2009, 118 : 37 - 52
  • [2] Neuropathology of familial Alzheimer's disease
    Revesz, T
    [J]. NEUROBIOLOGY OF AGING, 2002, 23 (01) : S148 - S148
  • [3] The neuropathology of Alzheimer's disease
    McKeel, D
    [J]. FASEB JOURNAL, 2004, 18 (04): : A404 - A404
  • [4] Neuropathology of Alzheimer's Disease
    Trejo-Lopez, Jorge A.
    Yachnis, Anthony T.
    Prokop, Stefan
    [J]. NEUROTHERAPEUTICS, 2022, 19 (01) : 173 - 185
  • [5] Neuropathology of Alzheimer's disease
    Mott, RT
    Hulette, CM
    [J]. NEUROIMAGING CLINICS OF NORTH AMERICA, 2005, 15 (04) : 755 - +
  • [6] Neuropathology of Alzheimer's Disease
    Perl, Daniel P.
    [J]. MOUNT SINAI JOURNAL OF MEDICINE, 2010, 77 (01): : 32 - 42
  • [7] Neuropathology of Alzheimer's disease
    Hauw, JJ
    Escourolle, F
    Colle, MA
    Duyckaerts, C
    [J]. ANNALES DE PATHOLOGIE, 2000, 20 (05) : 448 - 457
  • [8] Neuropathology of Alzheimer’s Disease
    Jorge A. Trejo-Lopez
    Anthony T. Yachnis
    Stefan Prokop
    [J]. Neurotherapeutics, 2022, 19 : 173 - 185
  • [9] Familial and sporadic Alzheimer's disease: Neuropathology cannot exclude a final common pathway
    Lippa, CF
    Saunders, AM
    Smith, TW
    Swearer, JM
    Drachman, DA
    Ghetti, B
    Nee, L
    PulaskiSalo, D
    Dickson, D
    Robitaille, Y
    Bergeron, C
    Crain, B
    Benson, MD
    Farlow, M
    Hyman, BT
    StGeorgeHyslop, P
    Roses, AD
    Pollen, DA
    [J]. NEUROLOGY, 1996, 46 (02) : 406 - 412
  • [10] The genetics and neuropathology of Alzheimer’s disease
    Gerard D. Schellenberg
    Thomas J. Montine
    [J]. Acta Neuropathologica, 2012, 124 : 305 - 323